Contingency Management for Depression and Cannabis Use
(CLEAR Trial)
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators.
Research shows that Contingency Management (CM), which uses rewards to encourage positive behavior like staying off cannabis, is effective in helping people reduce cannabis use and achieve abstinence, especially when combined with other therapies like cognitive behavioral therapy. Studies found that CM led to higher abstinence rates in people with cannabis dependence and those with mental health disorders like depression.
12345Contingency management (CM) is generally considered safe as it uses positive reinforcement to encourage behavior change, and it has been used effectively in various substance use treatments without significant safety concerns reported.
12346Contingency Management is unique because it uses positive reinforcement, like vouchers for goods or services, to encourage cannabis abstinence, which is different from other therapies that might focus on counseling or medication. This approach has shown success in increasing abstinence rates, especially when combined with other therapies like cognitive-behavioral therapy.
13678Eligibility Criteria
This trial is for adolescents aged 12-18 who experience depression or suicidal thoughts and use cannabis. It aims to understand how cannabis affects their mood and risk of suicide, with the goal of creating better interventions.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Participants complete a 2-week baseline phase involving real-time, ambulatory smartphone monitoring while using cannabis as usual
Randomized Treatment
Participants are randomized to either 8 weeks of cannabis abstinence with contingency management or non-contingent monitoring with no abstinence requirement
Follow-up
Participants are monitored for safety and effectiveness after treatment
Participant Groups
Contingency management for cannabis abstinence is already approved in United States, European Union, Canada for the following indications:
- Substance Abuse Treatment
- Cannabis Use Disorder
- Substance Abuse Treatment
- Cannabis Use Disorder
- Substance Abuse Treatment
- Cannabis Use Disorder